Why the study?
Does empagliflozin improve cardiac function and reduce fibrosis and inflammation in non-diabetic mice treated with doxorubicin?
Population
Doxorubicin-treated mice
Comparison
Empagliflozin
Authors
Loading...
Hypothesis-generating for empagliflozin in doxorubicin cardiotoxicity; leaves open translation to patients.
Does empagliflozin improve cardiac function and reduce fibrosis and inflammation in non-diabetic mice treated with doxorubicin?
Empagliflozin provides proof of concept for reducing doxorubicin-induced cardiotoxicity and improving cardiac function in non-diabetic models.
Quagliariello et al. (2021) studied this question.